TL;DR: Insilico Medicine just started Phase III trials for rentosertib, an oral TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) where both the drug target and the molecule itself were generated by AI (PandaOmics + Chemistry42), not pulled from an existing library. Phase IIa showed a real FVC improvement vs placebo, but it was a small, safety-primary trial — Phase III (320 patients, 52 weeks) is the actual test.

Why this one's different from the usual "AI drug discovery" story

Most AI-pharma headlines are about speed — screening more compounds faster. This one's making a harder claim: novel target, novel chemistry, and now a Phase III readout on the way, all with a public peer-reviewed trail.

![Insilico Pharma.AI discovery pipeline from PandaOmics target identification through Chemistry42 molecular design to Phase III trial for rentosertib](https://mer.vin/wp-content/uploads/2026/07/insilico-rentosertib-pipeline.png)

- Target ID: PandaOmics mined multi-omics data, clinical outcomes, and literature and ranked TNIK as a top IPF target — a kinase involved in Wnt, TGF-β, Hippo/YAP-TAZ, JNK, and NF-κB signaling, completely outside the RTK pathways every currently approved antifibrotic hits.
- Molecule design: Chemistry42 used generative reinforcement learning (GENTRL) to design molecules from scratch to fit the TNIK pocket. 79 synthesized, 55 advanced to preclinical, reaching a preclinical candidate in ~18 months vs a typical 2.5–4 years.
- Trial strategy: Insilico's Medicine42/inClinico platform was used to help design the clinical trial itself.

What Phase IIa (GENESIS-IPF) actually showed

Published in *Nature Medicine* — 71 patients, 22 sites in China, randomised to placebo or one of three rentosertib doses over 12 weeks. Important detail: safety was the primary objective, lung function change was exploratory, not a powered efficacy endpoint.

- Placebo: −20.3 mL FVC change at 12 weeks
- Rentosertib 60 mg once daily: +98.4 mL FVC change at 12 weeks
- Adverse events similar across arms
- Exploratory biomarkers consistent with anti-fibrotic/anti-inflammatory TNIK modulation

That's a real signal, but with a 71-person, single-country, safety-first trial, it's the kind of result that needs a much bigger confirmatory trial before anyone should treat it as proven efficacy — which is exactly what's happening now.

The Phase III trial

Started 7 July 2026. Randomised, double-blind, placebo-controlled, parallel-group. 320 patients across 47 centres, all in China currently. Once-daily rentosertib for 52 weeks. Primary endpoint: annual rate of FVC decline. Key secondary: time to first disease progression event. Registered as NCT07687459 / CTR20262475.

This is the endpoint that matters — a 52-week decline-rate measure is a much harder bar than a 12-week exploratory snapshot, and IPF trials have a history of signals shrinking or disappearing when they scale up.

The aging/senescence angle (and why it's not the headline)

Phase II also ran proteomic aging clocks (ProtAge, OrganAge, ipfP3GPT, PAC, SenMayo, CellAge) alongside standard endpoints, and separate research in *Aging and Disease* found TNIK inhibition shows senomorphic activity (reduced SASP and ECM remodelling markers) in cellular models. Interesting mechanistic tie-in to aging biology, but it's mechanistic support — not evidence rentosertib works as an anti-aging drug. Worth flagging because this kind of data tends to get oversold in AI-pharma coverage.

Evidence trail (for anyone who wants to actually check the sources)

- Nature Biotechnology — discovery-to-clinic paper: PandaOmics target ID, Chemistry42 design, preclinical efficacy, Phase I PK/safety
- Journal of Medicinal Chemistry — TNIK inhibitor chemotypes, co-crystal structure
- Nature Medicine — GENESIS-IPF Phase IIa results
- Aging and Disease — TNIK senomorphic activity in cellular models

Caveats worth keeping in mind

- Phase III can absolutely still fail — that's the whole point of running it
- Phase IIa's FVC gain was exploratory, over just 12 weeks, in a small trial
- Initial Phase III enrollment is entirely China-based — open question on how that translates to FDA/EMA pathways
- No head-to-head vs existing antifibrotics (nintedanib, pirfenidone) — unclear if this ends up as a replacement or a combo therapy
- "AI discovered this drug" bundles multiple distinct systems (PandaOmics, Chemistry42, Medicine42) and likely still involved real human chemist judgment at each selection step (only 55 of 79 molecules advanced)

Bottom line

This is genuinely one of the more complete public discovery-to-Phase-III arcs in AI drug discovery, with a real peer-reviewed trail instead of just press releases. Whether it validates the "AI can find genuinely novel biology" claim or just the "AI can move fast" claim depends entirely on how that 52-week Phase III readout turns out.

Media source (Article): https://mer.vin/2026/07/insilico-rentosertib-phase-iii-ai-discovered-tnik-drug-for-pulmonary-fibrosis-explained/
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2025/01/AI-News-White-1.png
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2026/07/insilico-medicine-advances-ai-drug-for-ipf-phase-iii-trials-lung-respiratory-1024x768.jpg
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2025/08/ai-expo-banner-2025.png
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2026/06/Airia-webinar.png
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2025/01/300x600.png
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2026/07/LOreal-Mondelez-and-Nestle-use-AI-to-speed-product-development-1024x683.jpg
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2026/07/15e92e81-a3c3-4e2a-a43b-ed5befb787c3-p01pqw85.jpg.jpg
Media source (Content source): https://www.artificialintelligence-news.com/wp-content/uploads/2025/01/cropped-AI-News-White-1024x196.png

---

[Read more on mer.vin](https://mer.vin/2026/07/insilico-rentosertib-phase-iii-ai-discovered-tnik-drug-for-pulmonary-fibrosis-explained/)

Insilico Rentosertib Phase III: AI-Discovered TNIK Drug for Pulmonary Fibrosis Explained